Literature DB >> 15180511

Immunotoxins and other conjugates: pre-clinical studies.

A Bolognesi1, L Polito.   

Abstract

A wide variety of conjugates containing RIPs, of either chemical or recombinant type, have been made and tested against dangerous cells in vitro and in animal models. Many of these pre-clinical studies will be reviewed here dividing them on the basis of the target cell and the surface molecule specifically recognized.

Mesh:

Substances:

Year:  2004        PMID: 15180511     DOI: 10.2174/1389557043403864

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  18 in total

1.  Ribosome depurination is not sufficient for ricin-mediated cell death in Saccharomyces cerevisiae.

Authors:  Xiao-Ping Li; Marianne Baricevic; Hemalatha Saidasan; Nilgun E Tumer
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

2.  Crystallization and preliminary X-ray diffraction data analysis of stenodactylin, a highly toxic type 2 ribosome-inactivating protein from Adenia stenodactyla.

Authors:  Giovanna Tosi; Simona Fermani; Giuseppe Falini; Letizia Polito; Massimo Bortolotti; Andrea Bolognesi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-12-25

3.  Expression and purification of cysteine introduced recombinant saporin.

Authors:  Emine Günhan; Mimi Swe; Mine Palazoglu; John C Voss; Leo M Chalupa
Journal:  Protein Expr Purif       Date:  2007-11-19       Impact factor: 1.650

4.  Transition State Structure of RNA Depurination by Saporin L3.

Authors:  Hongling Yuan; Christopher F Stratton; Vern L Schramm
Journal:  ACS Chem Biol       Date:  2016-03-08       Impact factor: 5.100

Review 5.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

Review 6.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

Review 7.  Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy.

Authors:  José M Ferreras; Lucía Citores; Rosario Iglesias; Pilar Jiménez; Tomás Girbés
Journal:  Toxins (Basel)       Date:  2011-04-29       Impact factor: 4.546

Review 8.  Pokeweed antiviral protein, a ribosome inactivating protein: activity, inhibition and prospects.

Authors:  Artem V Domashevskiy; Dixie J Goss
Journal:  Toxins (Basel)       Date:  2015-01-28       Impact factor: 4.546

9.  TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.

Authors:  Emily Cheng; Cheryl L Armstrong; Rebeca Galisteo; Jeffrey A Winkles
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

10.  X-ray sequence and crystal structure of luffaculin 1, a novel type 1 ribosome-inactivating protein.

Authors:  Xiaomin Hou; Minghuang Chen; Liqing Chen; Edward J Meehan; Jieming Xie; Mingdong Huang
Journal:  BMC Struct Biol       Date:  2007-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.